Home / About the group / Visitors and news

Visitors and news


Video: The Atlas of Breast Cancer Early Detection with Dr Susan Cherian

23/01/2023
Dr Susan Cherian, Head of the Pathology Department at the Bhabha Atomic Research Centre (BARC) Hospital, Mumbai, India, presents the Atlas of Breast Cancer Early Detection. The Atlas provides a guide to the multi-disciplinary approach for diagnosis of breast cancer, including information relating to the detailed clinical breast examination (CBE), diagnostic imaging, and pathological confirmation for every case described in this learning tool. The examples and images are an invaluable resource for healthcare workers to train them in diagnosis and differentiation of breast lumps. The Atlas also includes imagery of breast cancer screening and post-operative surveillance. View the video.

New release (January) of the CanScreen5 platform with new country data

03/01/2023
The CanScreen5 IARC Secretariat, following support of country collaborators and validation by our scientific committee, is happy to announce the availability on the CanScreen5 platform of the following country factsheets: Canada (Nova Scotia province data).
Visit the CanScreen5 website to explore characteristics and performance of cancer screening programmes across the globe in more than 77 countries.

January is cervical cancer awareness month!

02/01/2023
Throughout January, the International Agency for Research on Cancer (IARC) will mark Cervical Cancer Awareness Month with a series of posts, including tweets, interviews, and infographics. Stay tuned to the IARC website, www.iarc.fr, the IARC Twitter account, @IARCWHO, and the IARC YouTube channel, IARC WHO, during January to learn more about cervical cancer and the worldwide initiative to eliminate this disease as a public health problem. Read the IARC news

New release of the CanScreen5 cancer screening factsheets

28/12/2022
The CanScreen5 IARC Secretariat, following support of country collaborators and validation by our scientific committee, is happy to announce the availability of the new cancer screening fact sheet. Visit the CanScreen5 website to explore characteristics and performance of cancer screening programmes across the globe in more than 76 countries.

News: Evaluation of new HPV vaccine by IARC and partners supports recommendation to grant marketing authorization for the vaccine

05/07/2022
Scientists from the International Agency for Research on Cancer (IARC) were part of a unique collaboration between the Department of Biotechnology of the Government of India, the United States National Institutes of Health, and the Bill & Melinda Gates Foundation to support the evaluation of a quadrivalent human papillomavirus (HPV) vaccine manufactured by the Serum Institute of India (SII) in females and males aged 9–26 years. This unique model of public–private partnership resulted in a successful and timely completion of phase II and phase III vaccine efficacy trials, despite the threat posed by the COVID-19 pandemic. On 15 June 2022, after reviewing the study outcomes, the Subject Expert Committee (SEC) on Vaccines to advise the Drugs Controller General of India recommended granting marketing authorization for the new vaccine for females and males aged 9–26 years.
Read the IARC news.

New release (June) of the CanScreen5 platform with new country data

01/07/2022
The CanScreen5 IARC Secretariat, following support of country collaborators and validation by our scientific committee, is happy to announce the availability on the CanScreen5 platform of the following country factsheets: Bahamas, Cuba, Dominican Republic, Guyana, and Zambia.
Visit the CanScreen5 website to explore characteristics and performance of cancer screening programmes across the globe in more than 76 countries.

New publication: Effectiveness of artificial intelligence-assisted decision-making to improve vulnerable women's participation in cervical cancer screening in France: a cluster randomized controlled trial (AppDate-You)

03/06/2022
This new article describes the protocol AppDate-You of a two-arm cluster randomized controlled trial to be conducted in the Occitanie region, France. The objective of the study is to evaluate the effectiveness of a chatbot-based decision aid to improve vulnerable women's participation in the HPVss detection-based CCS care pathwayin the HPVss detection-based CCS care pathway. This study is supported by The French National Cancer Institute (INCa).
View the article.

New publication: Evaluation of effectiveness, acceptability, and safety of thermal ablation in the treatment of cervical neoplasia in Burundi

23/05/2022
Cervical cancer remains a major public health issue in resource-constrained settings. Appropriate management of precancer lesions is a key strategy to achieve cervical cancer elimination. Many low-income countries provide cryotherapy as ablative treatment while thermal ablation (TA) is a more practical and sustainable alternative, although more evidence is needed. This article published in IJC, reports the efficacy of thermal ablation based on the cure rate at 12 months and its potential use in the context of the “screen-and-treat” approach in Burundi.
View the article.

CBIG-SCREEN project: field visit to Estonia

16-05-2022 – 19-05-2022
Estonia is the second country visited within the CBIG-SCREEN project to assess the capacity of cervical cancer screening related services. Drs Isabel Mosquera and Keitly Mensah travelled to screening, and colposcopy and treatment facilities in Tallinn and the county of Ida-Viru. This capacity assessment is key to develop the intervention in a later phase of the project.

New publication: Screening technologies for cervical cancer: Overview

16/05/2022
This new article reviewed all cervical screening tools and technologies available currently like cytology, liquid based cytology, HPV testing, visual screening tests (e.g. VIA) and discussed about the strategies to manage of women positive any screening test.
View the article.

First page    Previous page   Next page     Last page

25 avenue Tony Garnier CS 90627 69366, LYON CEDEX 07 France - Tel: +33 (0)4 72 73 84 85
© IARC 2024 - Terms of use  -  Privacy Policy.